Form 4: AN2 Therapeutics Executive Stephen David Prior Reports Changes in Beneficial Ownership

Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On November 4, 2024, Prior was granted 10,125 Restricted Stock Units (RSUs) and options to purchase 20,250 shares of common stock at an exercise price of $1.08.
• The RSUs vest 1/4th annually over four years from November 4, 2024, subject to continuous service.
• An existing balance of 17,500 RSUs will continue to vest through December 31, 2024, with remaining RSUs vesting on January 1, 2025, and January 1, 2026.
• The stock options vest monthly over four years from November 4, 2024, until fully vested on November 4, 2028, subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and aligns management interests with shareholders.

Positives

• The grant of RSUs and stock options to the Chief Strategy Officer aligns his interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options incentivize long-term commitment and performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grants incentivize the Chief Strategy Officer to contribute to the company's long-term success, benefiting shareholders.

Key Dates